SCHEMBL418792

SCHEMBL418792

O=C(Nc1nc2ccccc2[nH]1)c1cscn1

nearest known ligand 0.60

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 12/20 0.60
RAB9A P51151 11/20 0.60
SMN1; SMN2 Q16637 5/20 0.60
PKM P14618 4/20 0.60
MAOB P27338 1/20 0.60
ADORA2A P29274 1/20 0.60
KDM4E B2RXH2 2/20 0.57
MEN1 O00255 3/20 0.56
KMT2A Q03164 3/20 0.56
LMNA P02545 2/20 0.56
CYP3A4 P08684 1/20 0.56
TP53 P04637 2/20 0.55
SCD O00767 1/20 0.55
GAA P10253 1/20 0.55
OPRK1 P41145 1/20 0.55
KLF5 Q13887 1/20 0.55
HSD17B10 Q99714 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11733232 0.84 CYP3A4 (0.49) NPC1RAB9ASMN1; SMN2PKMMAOB
SCHEMBL11709899 0.83 NPC1 (0.67) NPC1RAB9ASMN1; SMN2PKMMAOB
SCHEMBL421032 0.83 SCD (0.58) NPC1RAB9ASMN1; SMN2PKMMAOB
SCHEMBL11728514 0.80 NPC1 (0.62) NPC1RAB9ASMN1; SMN2PKMMAOB
SCHEMBL11811427 0.79 NPC1 (0.60) NPC1RAB9ASMN1; SMN2PKMMAOB
SCHEMBL418190 0.79 SMN1; SMN2 (0.52) NPC1RAB9ASMN1; SMN2KDM4EMEN1
SCHEMBL11733228 0.79 LMNA (0.52) NPC1RAB9ASMN1; SMN2PKMMAOB
SCHEMBL11733883 0.78 NPC1 (0.62) NPC1RAB9ASMN1; SMN2PKMMAOB
SCHEMBL11731331 0.77 NPC1 (0.62) NPC1RAB9ASMN1; SMN2PKMMAOB
SCHEMBL22182986 0.77 NPC1 (0.64) NPC1RAB9ASMN1; SMN2PKMMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8106048-B2 protozoal infestations in humans and animals, by bacteria, viruses or proteinaceous agents; neurological diseases or disorders; ischemia and/or reperfusion injury; 4-(4-Ethoxycarbonyl-4,5-dihydro-thiazol-2-yl)-piperidine-1-carboxylic acid t-butyl ester 4SC AG (DE) 2012-01-31 US disclosed
US-20120022068-A1 NOVEL HETEROCYCLIC NF-kB INHIBITORS 4SC AG (DE) 2012-01-26 US disclosed
US-4011236-A N-(BENZIMIDAZOL-2-YL)ARYLCARBOXAMIDES AS ULTRAVIOLET (UV) LIGHT ABSORBERS MERCK & CO., INC. (US) 1977-03-08 US disclosed
US-4009164-A Novel 2-substituted-1,2,4-thiadiazole-[2,3-a]-benzimidazoles and process for their preparation SYNTEX (U.S.A.) INC. (US) 1977-02-22 US disclosed
US-3976654-A FUNGICIDE SYNTEX (U.S.A.) INC. (US) 1976-08-24 US disclosed
US-3946031-A FUNGICIDES SYNTEX INC. (US) 1976-03-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022068-A1 NOVEL HETEROCYCLIC NF-kB INHIBITORS NFKB2, NFKBIA, NFRKB NPC1 2626/4885RAB9A 3958/4885SMN1; SMN2 3959/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.